Glen Eagle Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $982K | Buy |
8,168
+302
| +4% | +$34.9K | 0.14% | 112 |
|
|
2025
Q4 | $828K | Sell |
7,866
-265
| -3% | -$24.9K | 0.11% | 123 |
|
|
2025
Q3 | $682K | Buy |
8,131
+182
| +2% | +$15K | 0.09% | 145 |
|
|
2025
Q2 | $629K | Sell |
7,949
-568
| -7% | -$45.1K | 0.1% | 131 |
|
|
2025
Q1 | $764K | Sell |
8,517
-162
| -2% | -$15.1K | 0.13% | 114 |
|
|
2024
Q4 | $863K | Buy |
8,679
+1
| +0% | +$103 | 0.14% | 107 |
|
|
2024
Q3 | $985K | Buy |
8,678
+161
| +2% | +$19.1K | 0.17% | 102 |
|
|
2024
Q2 | $1.05M | Sell |
8,517
-457
| -5% | -$58.9K | 0.19% | 92 |
|
|
2024
Q1 | $1.18M | Sell |
8,974
-94
| -1% | -$11.6K | 0.22% | 83 |
|
|
2023
Q4 | $989K | Sell |
9,068
-44
| -0.5% | -$4.57K | 0.21% | 95 |
|
|
2023
Q3 | $938K | Sell |
9,112
-3,763
| -29% | -$406K | 0.22% | 94 |
|
|
2023
Q2 | $1.49M | Sell |
12,875
-1,669
| -11% | -$190K | 0.34% | 63 |
|
|
2023
Q1 | $1.55M | Buy |
14,544
+6,663
| +85% | +$719K | 0.39% | 55 |
|
|
2022
Q4 | $874K | Buy |
7,881
+91
| +1% | +$9.3K | 0.24% | 88 |
|
|
2022
Q3 | $671K | Buy |
7,790
+149
| +2% | +$13.3K | 0.19% | 100 |
|
|
2022
Q2 | $697K | Buy |
7,641
+422
| +6% | +$37.4K | 0.19% | 104 |
|
|
2022
Q1 | $592K | Sell |
7,219
-217
| -3% | -$17.1K | 0.15% | 128 |
|
|
2021
Q4 | $570K | Sell |
7,436
-617
| -8% | -$49.1K | 0.15% | 134 |
|
|
2021
Q3 | $605K | Hold |
8,053
| – | – | 0.18% | 127 |
|
|
2021
Q2 | $626K | Sell |
8,053
-34
| -0.4% | -$2.53K | 0.19% | 110 |
|
|
2021
Q1 | $595K | Buy |
8,087
+25
| +0.3% | +$1.84K | 0.21% | 108 |
|
|
2020
Q4 | $629K | Sell |
8,062
-1,286
| -14% | -$98.4K | 0.25% | 84 |
|
|
2020
Q3 | $740K | Buy |
9,348
+492
| +6% | +$38.5K | 0.33% | 66 |
|
|
2020
Q2 | $653K | Sell |
8,856
-25
| -0.3% | -$1.88K | 0.34% | 68 |
|
|
2020
Q1 | $652K | Buy |
8,881
+932
| +12% | +$73.2K | 0.46% | 50 |
|
|
2019
Q4 | $690K | Buy |
7,949
+310
| +4% | +$25.5K | 0.37% | 63 |
|
|
2019
Q3 | $614K | Sell |
7,639
-27
| -0.4% | -$2.16K | 0.41% | 59 |
|
|
2019
Q2 | $613K | Sell |
7,666
-66
| -0.9% | -$5.05K | 0.42% | 57 |
|
|
2019
Q1 | $614K | Buy |
7,732
+959
| +14% | +$71.7K | 0.45% | 54 |
|
|
2018
Q4 | $494K | Buy |
6,773
+114
| +2% | +$8.05K | 0.42% | 58 |
|
|
2018
Q3 | $451K | Buy |
6,659
+325
| +5% | +$20.7K | 0.32% | 72 |
|
|
2018
Q2 | $367K | Buy |
6,334
+564
| +10% | +$31.8K | 0.29% | 79 |
|
|
2018
Q1 | $300K | Sell |
5,770
-116
| -2% | -$6.26K | 0.25% | 92 |
|
|
2017
Q4 | $316K | Buy |
5,886
+30
| +0.5% | +$1.66K | 0.27% | 83 |
|
|
2017
Q3 | $358K | Sell |
5,856
-63
| -1% | -$3.82K | 0.33% | 73 |
|
|
2017
Q2 | $362K | Buy |
5,919
+239
| +4% | +$14.5K | 0.29% | 89 |
|
|
2017
Q1 | $344K | Sell |
5,680
-173
| -3% | -$10.5K | 0.3% | 90 |
|
|
2016
Q4 | $329K | Buy |
+5,853
| New | +$343K | 0.3% | 91 |
|
Other funds holding MRK
VCM
VPM
Glen Eagle Advisors's MRK Position: Q1 2026 in Review
Glen Eagle Advisors increased its Merck (MRK) stake by 3.8% in Q1 2026, buying an estimated $34.9K and bringing the position to 8,168 shares worth $982K. The position accounts for 0.14% of the portfolio, ranked #112.
Glen Eagle Advisors first reported a position in MRK in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.55M in Q1 2023. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Glen Eagle Advisors held 8,168 shares of Merck worth $982K as of Q1 2026.
- Glen Eagle Advisors bought 302 Merck shares in Q1 2026, an estimated $34.9K.
- Merck made up 0.14% of Glen Eagle Advisors's portfolio in Q1 2026, its #112 holding.
- Glen Eagle Advisors first reported a position in Merck in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Merck position peaked at $1.55M in Q1 2023.
- 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.